‘magic mushroom’ users have lower risk of addiction: study

Psilocybin, the substance found in magic mushrooms, has been linked to a reduced risk of opioid addiction, a recent study conducted in the US found.

The survey found that psilocybin users were 30% less likely to become addicted to opioids than those who had never used hallucinogens.

Data collected between 2015 and 2019 showed that of the 214,505 respondents, those using psilocybin were also 17 to 34 percent less likely to develop symptoms of opioid dependence.

The study, led by Grant Jones, a Harvard University student in the Department of Psychology, theorized that psilocybin might block the brain’s chemical response to serotonin and dopamine, which have previously been linked to depression. addiction. Psychedelic experiences often associated with the use of hallucinogens may also be a factor in helping to treat addiction, as the researchers note that previous reports have suggested faith has positively aided in addiction. substance abuse rehabilitation.

While the results are preliminary and do not include other hallucinogens such as LSD or peyote, the authors say the survey lays the groundwork for essential trials aimed at finding a treatment for the opioid epidemic. all around the world.

These studies may also provide the necessary baseline evidence for an association between psilocybin and OUDs and maximize the ability of clinical trials to be ethical and safe to evaluate, the researchers said. potential therapeutic value of this compound.

Canada is no stranger to opioid addiction. Between January 2016 and September 2021, Health Canada reported 26,990 deaths from opioid intoxication; a number that continues to grow affecting thousands of Canadian families.

In Canada, similar trials have been conducted or are currently underway to explore how this compound can treat addiction and mental health problems. Ontario company Diamond Therapeutics recently concluded the first phase of clinical trials of low-dose, non-psychedelic psilocybin aimed at determining a non-psychotic but working dose for health treatments. mental. BC’s Numinus ( recently applied to Health Canada to test a “natural” Psilocybe extract. If approved, it will monitor 20 healthy subjects and how the body can absorb and tolerate the drug.

A recent study conducted by John Hopkins University School of Medicine found that these magic mushrooms were able to reduce symptoms of depression in a shorter treatment period than traditional antidepressants. system.

Source link


News7h: Update the world's latest breaking news online of the day, breaking news, politics, society today, international mainstream news .Updated news 24/7: Entertainment, the World everyday world. Hot news, images, video clips that are updated quickly and reliably

Related Articles

Back to top button